Advanced Biostatistics March 1, 2006 First Exam

Name_____

Directions: *Thoroughly, clearly, neatly and correctly* answer the following 3 exercises and 3 short answer questions in the space given (or on the back), showing all relevant calculations. Use $\alpha = 5\%$ throughout.

Exercises

- 1. (1.5 + 3 + 1.5 = 6 points) Amphetamine is a drug that it is felt suppresses appetite. To test this effect, a pharmacologist randomly allocated 24 rats to receive one of three treatment groups (to receive an injection of amphetamine at one of two dosage levels or an injection of saline solution, i.e., amphetamine at zero dose level). She then measured the amount of food consumed by each animal in the 3-hour period following injection, and these data are reproduced, graphed and analyzed on p.1 of the *Appendix*. Her goal is to test whether there is a significant linear relationship between amphetamine dose and food consumption.
 - (a) State the assumptions that must be made for this SLR analysis *in the context of this study*. Be specific and clear.

(b) Test whether there is a significant linear relationship between amphetamine dose and food consumption. Be sure to write out the statistical model function, the null and alternative hypotheses, value of the relevant test statistic (TS) and distribution (including df), p-value, and your detailed and clear conclusion.

Statistical Model Function		
Null		Alternative
TS	df	p-value

Detailed and clear conclusion

(c) Clearly interpret the estimate of the slope parameter in this SLR model in the context of this study. Give the units.

- 2. (4 + 5 = 9) The new cholesterol-lowering supplement, Fibralo, was studied in a double-blind study against the marketed reference supplement, Gemfibrozil, in 34 non-insulin dependent diabetic patients. The study's objective was to compare the mean decrease in triglyceride levels (denoted "trichg" in the dataset) between the two treatment groups. The degree glycemic control, measured by hemoglobin A_{1c} levels (denoted "hgba1c" in the dataset), was thought to be an important factor as well. This covariate was measured at the start of the study and is shown in the listing on p.2 in the *Appendix* with the percent changes in triglycerides from pre-treatment to the end of the 10-week trial. The data are graphed and analyzed using Minitab on pp.3-4 of the *Appendix*.
 - (a) After removing the hemoglobin covariate, test whether there is a difference in mean responses between supplements. *For this part only, assume that the respective lines are parallel*. Give the relevant Minitab output # to use in the analysis, null and alternative hypothesis, observed test statistic and distribution (including df), p-value and detailed conclusion.

Use Minitab output # V	Vrite out model function: $\underline{E(Y)} =$	
Null	Alternative	
TS	df p-value	

Detailed conclusion

(b) Dropping (no longer making) the parallelism assumption used in part (a), test whether a single regression line could be used for the two groups for the data graphed at the top of p.3 in the *Appendix*, clearly writing out your statistical model, your new hypotheses, calculated test statistic and its distribution (with df), p-value, and your detailed and clear conclusion. Identify the relevant output #(s).

Write out the model function: $\underline{E(Y)} =$						
Null hypothesis	-					
Alternative hypothesis	-					
Showing your calculations, give the calculated test statistic						

Degrees of freedom

p-value _____

Detailed and clear conclusion

- (0.75 + 0.75 + 1 + 2 + 2 + 1 = 7.5 points) Cardiac researchers at a major U.S. research hospital conducted a *crossover* study of the effects of three drug treatments (labeled A, B and C) on heart rates of randomly chosen elderly individuals. The data are analyzed in SAS, and the SAS programs and outputs are given on pages 5 and 6 of the *Appendix*. Note that each of these programs includes a term for the carryover effect of the previous treatment (labeled "residue" here).
 - (a) How many patients were used in this study?
 - (b) How many sequences of the three drugs were used in this study?
 - (c) Do you feel that the washout period used in this study (two weeks) was sufficient to remove the effects of the previous drug before the next one was given? Why or why not? Be specific (give relevant p-value).
 - (d) Using only the **<u>First SAS Output</u>**, do you feel that the treatment averages differ? Be specific, giving your hypotheses, value of the test statistic, its distribution (including degrees of freedom), p-value, and a detailed conclusion.

(e) Using only the <u>Second SAS Output</u>, do you feel that the treatment averages differ? Be specific, giving your hypotheses, value of the test statistic, its distribution (including degrees of freedom), p-value, and a detailed conclusion.

(f) Summarize your findings for this study in terms of whether the treatments differ, and give the logical "next step" to help us make our final conclusion regarding these treatments.

Short Answer Questions (2.5 points each) - Be specific and clear in your responses

4. Returning to Exercise 2(a), if the covariate (hgba1c) was ignored and we wanted to compare the treatment means, what would our conclusion be and why? The correct output here is output #

5. A medical researcher wanted to study the efficacy of six drugs (labeled A – F), found 3 patients to whom she would randomize the drugs, but was told that a patient could only take four of the six drugs. She decided to give drugs A, B, D and E to the first patient, drugs B, C, E and F to the second patient, and drugs A, C, D and F to the third patient.

Why is this block design "incomplete"?

Why is this incomplete block design not "balanced"?

6. You collect count data for males and females and survival rates from a type of surgery, and you arrange the data into a two by two table with males on the first row and females on the second row, survival counts in the first column and deceased counts in the second column.

Your calculated estimated odds ratio is 2.8239. Clearly interpret this estimate in the context of this setting.

Your calculated 90% confidence interval for the true odds ratio is (1.2997,6.1356). Clearly interpret this interval in the context of this setting and give its *ramifications*.

Exercise 1 output

	Dose = 0.0 mg/kg	Dose = 2.5 mg/kg	Dose = 5.0 mg/kg
	112.6	73.3	38.5
	102.1	84.8	81.3
	90.2	67.3	57.1
	81.5	55.3	62.3
	105.6	80.7	51.5
	93.0	90.0	48.3
	106.6	75.5	42.7
	108.3	77.1	57.9
Mean (g/kg)	100.0	75.5	55.0
SD(g/kg)	10.7	10.7	13.3
No. of animals	8	8	8



Output 1.1. Regression Analysis: foodcons versus dose								
The regression equation is foodcons = 99.3 - 9.01 dose								
Predictor Constant dose	Coef 99.331 -9.008	SE Coef 3.680 1.140	т 26.99 -7.90	P 0.000 0.000				
S = 11.40	R-Sq =	73.9% R·	-Sq(adj) = 7	12.8%				
Analysis of Va	riance							
Source	DF	SS	MS	F	P			
Regression	1	8113.5	8113.5	62.41	0.000			
Residual Error	22	2859.9	130.0					
Total	23	10973.4						

Exercise 2 output

Printout of data

trt	hgba1c	trichg	trtfib	product
FIB	7.0	5	1	7.0
FIB	6.0	10	1	6.0
FIB	7.1	-5	1	7.1
FIB	8.6	-20	1	8.6
FIB	6.3	0	1	6.3
FIB	7.5	-15	1	7.5
FIB	6.6	10	1	6.6
FIB	7.4	-10	1	7.4
FIB	5.3	20	1	5.3
FIB	6.5	-15	1	6.5
FIB	6.2	5	1	6.2
FIB	7.8	0	1	7.8
FIB	8.5	-40	1	8.5
FIB	9.2	-25	1	9.2
FIB	5.0	25	1	5.0
FIB	7.0	-10	1	7.0
GEM	5.1	10	0	0.0
GEM	6.0	15	0	0.0
GEM	7.2	-15	0	0.0
GEM	6.4	5	0	0.0
GEM	5.5	10	0	0.0
GEM	6.0	-15	0	0.0
GEM	5.6	-5	0	0.0
GEM	5.5	-10	0	0.0
GEM	6.7	-20	0	0.0
GEM	8.6	-40	0	0.0
GEM	6.4	-5	0	0.0
GEM	6.0	-10	0	0.0
GEM	9.3	-40	0	0.0
GEM	8.5	-20	0	0.0
GEM	7.9	-35	0	0.0
GEM	7.4	0	0	0.0
GEM	5.0	0	0	0.0
GEM	6.5	-10	0	0.0

Exercise 2 output



Output 2.1. Regression Analysis: trichg versus hgba1c								
The regression trichg = 65.0	n equation - 10.6 hg	is balc						
Predictor	Coef	SE Coef	Т	P				
Constant	65.05	10.81	6.02	0.000				
hgbalc	-10.629	1.564	-6.80	0.000				
S = 10.85	R-Sq =	59.1% R-8	Sq(adj) = 5	7.8%				
Analysis of Va	ariance							
Source	DF	SS	MS	F	P			
Regression	1	5442.7	5442.7	46.21	0.000			
Residual Erro	r 32	3769.1	117.8					
Total	33	9211.8						

Output 2.2. Regression Analysis: trichg versus trtfib, hgba1c, product								
The regression trichg = 58.0	n equation + 26.0 tri	is tib - 10.3 h	gbalc - 2.3	30 product				
Predictor	Coef	SE Coef	Т	Р				
Constant	58.05	12.66	4.58	0.000				
trtfib	26.00	19.92	1.31	0.202				
hgba1c	-10.283	1.875	-5.49	0.000				
product	-2.304	2.867	-0.80	0.428				
s = 9.734	R-Sq = 6	59.1% R-S	q(adj) = 60	5.1%				
Analysis of Va	ariance							
Source	DF	SS	MS	F	P			
Regression	3	6369.3	2123.1	22.41	0.000			
Residual Erro	r 30	2842.5	94.7					
Total	33	9211.8						

Output 2.3. Regression Analysis: trichg versus trtfib

The regression equation is trichg = -10.3 + 6.22 trtfib Predictor Coef SE Coef T P Constant -10.278 3.927 -2.62 0.013trtfib 6.215 5.725 1.09 0.286S = 16.66 R-Sq = 3.6% R-Sq(adj) = 0.5%Analysis of Variance Source DF SS MS F P Regression 1 327.2 327.2 1.18 0.286Residual Error 32 8884.5 277.6Total 33 9211.8

Output 2.4. Regression Analysis: trichg versus trtfib, hgba1c								
The regression trichg = 64.6	n equation + 10.2 tr	is tfib - 11.3 h	lgbalc					
Predictor	Coef	SE Coef	Т	P				
Constant	64.593	9.643	6.70	0.000				
trtfib	10.222	3.363	3.04	0.005				
hgbalc	-11.268	1.410	-7.99	0.000				
S = 9.678	R-Sq =	68.5% R-S	6q(adj) = 6	6.4%				
Analysis of Va	ariance							
Source	DF	SS	MS	F	P			
Regression	2	6308.1	3154.0	33.67	0.000			
Residual Error	31	2903.7	93.7					
Total	33	9211.8						

```
proc glm;
    class pt seq per trt residue;
    model hr=seq pt(seq) per trt residue;
run;
```

First SAS Output for Exercise 3 -

The GLM Procedure							
Dependent Venichles hu							
Dependent variable: hr			-	-			
_			Sum	DT	_		
Source		DF	Squar	es Mean	Square	F Value	Pr > F
Model		29	6408.6944	14 220	.989464	3.91	<.0001
Error		42	2372.5833	33 56	.490079		
Corrected Total		71	8781.2777	78			
	R-Square	Co	oeff Var	Root MSE	hr I	Mean	
	0.729813	ç	9.301326	7.515988	80.8	0556	
Source		DF	Type I	SS Mean	Square	F Value	Pr > F
seq		5	508.9444	14 101	.788889	1.80	0.1333
pt(seq)		18	4692.3333	33 260	.685185	4.61	<.0001
per		2	146.7777	78 73	.388889	1.30	0.2835
trt		2	668.7777	78 334	.388889	5.92	0.0054
residue		2	391.8611	11 195	.930556	3.47	0.0404
Source		DF	Type III	SS Mean	Square	F Value	Pr > F
seq		5	701.1833	33 140	.236667	2.48	0.0466
pt(seq)		18	4692.3333	33 260	.685185	4.61	<.0001
per		1	6.7500	00 6	.750000	0.12	0.7313
trt		2	343.9500	00 171	.975000	3.04	0.0583
residue		2	391.8611	11 195	.930556	3.47	0.0404

→ Note that "trtb" is a contrast between treatments A and B, and "trtc" is a contrast between treatments A and C

```
data one;
input pt seq$ per basehr hr trt$ residue @@;
if trt='A' then do; trtb=-1; trtc=-1; end;
else if trt='B' then do; trtb=1; trtc=0; end;
else if trt='C' then do; trtb=0; trtc=1; end;
datalines;
(Datalines deleted)
proc glm;
class pt seq per residue;
model hr=seq pt(seq) per trtb trtc residue;
run;
```

Second SAS Output for Exercise 3 -

The GLM Procedure					
Dependent Variable: hr					
·		Sum of			
Source	DF	Squares	Mean Square	F Value	Pr > F
Model	29	6408.694444	220.989464	3.91	<.0001
Error	42	2372.583333	56.490079		
Corrected Total	71	8781.277778	i		
R-Squa	re Co	eff Var – R	oot MSE hr	Mean	
0.7298	13 9	.301326 7	.515988 80.8	0556	
Source	DF	Type I SS	Mean Square	F Value	Pr > F
seq	5	508.944444	101.788889	1.80	0.1333
pt(seq)	18	4692.333333	260.685185	4.61	<.0001
per	2	146.77778	73.388889	1.30	0.2835
trtb	1	320.333333	320.333333	5.67	0.0219
trtc	1	348.444444	348.444444	6.17	0.0171
residue	2	391.861111	195.930556	3.47	0.0404
Source	DF	Type III SS	Mean Square	F Value	Pr > F
seq	5	701.183333	140.236667	2.48	0.0466
pt(seq)	18	4692.333333	260.685185	4.61	<.0001
per	1	6.750000	6.750000	0.12	0.7313
trtb	1	217.800000	217.800000	3.86	0.0562
trtc	1	292.612500	292.612500	5.18	0.0280
residue	2	391.861111	195.930556	3.47	0.0404